Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy.
Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment.
Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer.